Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Monopar Therapeutics (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative cancer treatments, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. Chandler D. Robinson, MD, Monopar's CEO, will present at the conference. Key details include:
- Presentation will be webcast starting Monday, September 9, 2024 at 7:00 a.m. ET
- In-person one-on-one meetings will be held at the Lotte New York Palace, NY
- Conference dates: September 9 - 11, 2024
This event provides Monopar an opportunity to showcase its progress and connect with potential investors, potentially impacting its stock performance (MNPR).
Monopar Therapeutics (Nasdaq: MNPR), un'azienda biofarmaceutica in fase clinica che sviluppa trattamenti innovativi per il cancro, ha annunciato la sua partecipazione alla 26esima Conferenza Globale Annuale sugli Investimenti H.C. Wainwright. Chandler D. Robinson, MD, CEO di Monopar, presenterà alla conferenza. I dettagli chiave includono:
- La presentazione sarà trasmessa in webcast a partire da lunedì 9 settembre 2024 alle 7:00 ET
- Incontri in persona uno-a-uno si terranno presso il Lotte New York Palace, NY
- Date della conferenza: 9 - 11 settembre 2024
Questo evento offre a Monopar l'opportunità di mettere in mostra i propri progressi e connettersi con potenziali investitori, con un possibile impatto sulle sue performance azionarie (MNPR).
Monopar Therapeutics (Nasdaq: MNPR), una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos innovadores para el cáncer, ha anunciado su participación en la 26ª Conferencia Global Anual de Inversiones H.C. Wainwright. Chandler D. Robinson, MD, CEO de Monopar, presentará en la conferencia. Los detalles clave incluyen:
- La presentación se transmitirá en webcast comenzando el lunes 9 de septiembre de 2024 a las 7:00 a.m. ET
- Se llevarán a cabo reuniones personales uno a uno en el Lotte New York Palace, NY
- Fechas de la conferencia: 9 - 11 de septiembre de 2024
Este evento brinda a Monopar la oportunidad de mostrar su progreso y conectarse con inversores potenciales, lo que podría impactar en su rendimiento de acciones (MNPR).
모노파 테라퓨틱스(Monopar Therapeutics, Nasdaq: MNPR)는 혁신적인 암 치료제를 개발하는 임상 단계의 생명공학 회사로서 H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에 참석한다고 발표했습니다. 모노파의 CEO인 챈들러 D. 로빈슨, MD가 컨퍼런스에서 발표할 예정입니다. 주요 세부 사항은 다음과 같습니다:
- 발표는 2024년 9월 9일 월요일 오전 7시 (ET)부터 웹캐스트로 진행됩니다.
- 대면 1:1 미팅은 롯데 뉴욕 팰리스(Lotte New York Palace, NY)에서 진행됩니다.
- 컨퍼런스 날짜: 2024년 9월 9일 - 11일
이 행사는 모노파에게 자신의 진행 상황을 보여주고 잠재적인 투자자들과 연결할 수 있는 기회를 제공하며, 이는 주식 성과(MNPR)에 영향을 미칠 수 있습니다.
Monopar Therapeutics (Nasdaq: MNPR), une entreprise biopharmaceutique en phase clinique développant des traitements innovants contre le cancer, a annoncé sa participation à la 26ème Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. Chandler D. Robinson, MD, PDG de Monopar, présentera lors de la conférence. Les détails clés comprennent :
- La présentation sera diffusée en direct à partir de lundi 9 septembre 2024 à 7h00 ET
- Des réunions individuelles en personne se tiendront au Lotte New York Palace, NY
- Dates de la conférence : 9 - 11 septembre 2024
Cette événement offre à Monopar l'opportunité de mettre en valeur ses progrès et de se connecter avec des investisseurs potentiels, ce qui pourrait avoir un impact sur ses performances boursières (MNPR).
Monopar Therapeutics (Nasdaq: MNPR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das innovative Krebsbehandlungen entwickelt, hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt. Chandler D. Robinson, MD, der CEO von Monopar, wird auf der Konferenz eine Präsentation halten. Wichtige Details sind:
- Die Präsentation wird ab Montag, den 9. September 2024 um 7:00 Uhr ET als Webcast übertragen.
- Persönliche Einzelgespräche finden im Lotte New York Palace, NY statt.
- Konferenzdaten: 9. - 11. September 2024
Diese Veranstaltung bietet Monopar die Möglichkeit, seine Fortschritte zu zeigen und mit potenziellen Investoren in Kontakt zu treten, was sich möglicherweise auf die Aktienperformance (MNPR) auswirken könnte.
- None.
- None.
WILMETTE, Ill., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that Chandler D. Robinson, MD, Monopar’s Chief Executive Officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference. The Company’s presentation will be webcast beginning on Monday, September 9, 2024 at 7:00 a.m. ET. In person one-on-one meetings will take place at the Lotte New York Palace, NY, NY from September 9 - 11, 2024.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, Phase 1-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programs against solid cancers. For more information, visit: www.monopartx.com.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
Follow Monopar on social media for updates:
Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
FAQ
When is Monopar Therapeutics (MNPR) presenting at the H.C. Wainwright Global Investment Conference?
Where will the in-person meetings for Monopar Therapeutics (MNPR) take place during the conference?
What are the dates for the H.C. Wainwright Global Investment Conference that Monopar Therapeutics (MNPR) is attending?
Who will be presenting on behalf of Monopar Therapeutics (MNPR) at the investment conference?
